New potential for Prostate Cancer for those where radiation therapy has failed...BD
USHIFU, the clinical trial management provider for Focus Surgery, In
c. (Indianapolis, IN), is pleased to announce conditional written approval pending minor changes to the protocol from the FDA to begin a pivotal trial for the treatment of recurrent prostate cancer with the Sonablate(R) 500 in men who have failed external beam radiation therapy.
Dr. Herbert Lepor, Chairman of Urology at NYU School of Medicine and medical monitor for the trial said, "It is my pleasure to serve as the medical monitor for the prostate cancer clinical trial program evaluating the safety and effectiveness of the Sonablate(R) 500 HIFU device."
FDA Approves HIFU Clinical Trial For Recurrent Prostate Cancer
0 comments :
Post a Comment